Occam’s commitment to help meaningfully shape and build structure in high science platform companies has yielded another impressive result in the placement of Dan Marquess as CSO at Vicinitas, Dan Nomura’s latest creation that seeks to commercialize a compellingly novel approach to drugging the “undruggable.”
With $65M in the bank from Deerfield and a16z and with Marquess leading the scientific charge, Vicinitas is well positioned to deliver on the platform’s formidable potential around leveraging protein stabilization to develop a novel class of therapeutics.
Prior to Vicinitas, Marquess was the CSO at UNITY Biotechnology and prior to that role had spent more than 15 years at Theravance.
Dan earned his D.Phil in Chemistry from Oxford University and his undergraduate degree in Chemistry from Queens University.
